international stem cell corp - ISCO

ISCO

Close Chg Chg %
0.18 -0.01 -5.71%

Closed Market

0.17

-0.01 (5.71%)

Volume: 10.32K

Last Updated:

Feb 5, 2026, 1:38 PM EDT

Company Overview: international stem cell corp - ISCO

ISCO Key Data

Open

$0.14

Day Range

0.14 - 0.17

52 Week Range

0.08 - 0.27

Market Cap

$1.44M

Shares Outstanding

8.00M

Public Float

3.70M

Beta

0.33

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.02

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

7.04K

 

ISCO Performance

1 Week
 
17.86%
 
1 Month
 
17.86%
 
3 Months
 
17.02%
 
1 Year
 
81.32%
 
5 Years
 
N/A
 

ISCO Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About international stem cell corp - ISCO

International Stem Cell Corp. operates as a research and development company for the therapeutic market. It focuses on advancing potential clinical applications of human parthenogenetic stem cells for the treatment of various diseases of the central nervous system and liver diseases. The firm operates through three segments: Therapeutic Market, Biomedical Market and Anti-Aging Market. The Biomedical Market segment markets and sells primary human cell research products with two product categories, cells and media. The Anti-Aging market segment markets and sells a line of skincare products sold through two sales channels: ecommerce and professional. The ecommerce channel sells direct to customers through online orders, while professional sales are to spas, salons and other skincare providers. The Therapeutic Market segment focuses on the research and development of human parthenogenetic stem cells for the treatment of diseases of the central nervous system, liver diseases and is currently conducting clinical trials for the treatment of Parkinson's disease. The company was founded by William B. Adams, Kenneth C. Aldrich and Gregory S. Keller in June 2005 and is headquartered in San Diego, CA.

ISCO At a Glance

International Stem Cell Corp.
9745 Businesspark Avenue
San Diego, California 92131
Phone 1-760-940-6383 Revenue 9.09M
Industry Medical Specialties Net Income -209,000.00
Sector Health Technology 2024 Sales Growth 16.639%
Fiscal Year-end 12 / 2025 Employees 32
View SEC Filings

ISCO Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.072
Price to Book Ratio N/A
Price to Cash Flow Ratio 50.06
Enterprise Value to EBITDA 54.041
Enterprise Value to Sales 0.833
Total Debt to Enterprise Value 0.508

ISCO Efficiency

Revenue/Employee 283,906.25
Income Per Employee -6,531.25
Receivables Turnover 8.587
Total Asset Turnover 1.703

ISCO Liquidity

Current Ratio 0.759
Quick Ratio 0.514
Cash Ratio 0.262

ISCO Profitability

Gross Margin 57.666
Operating Margin -0.726
Pretax Margin -2.30
Net Margin -2.30
Return on Assets -3.917
Return on Equity -86.542
Return on Total Capital -4.964
Return on Invested Capital -40.077

ISCO Capital Structure

Total Debt to Total Equity 1,037.838
Total Debt to Total Capital 91.211
Total Debt to Total Assets 72.70
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital 2.732
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for International Stem Cell Corp - ISCO

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
7.18M 8.18M 7.79M 9.09M
Sales Growth
+0.67% +13.99% -4.78% +16.64%
Cost of Goods Sold (COGS) incl D&A
3.03M 3.35M 3.26M 3.85M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
551.00K 359.00K 194.00K 206.00K
Depreciation
460.00K 278.00K 112.00K 124.00K
Amortization of Intangibles
91.00K 81.00K 82.00K 82.00K
COGS Growth
+5.36% +10.71% -2.60% +17.87%
Gross Income
4.15M 4.83M 4.53M 5.24M
Gross Income Growth
-2.49% +16.39% -6.29% +15.75%
Gross Profit Margin
+57.83% +59.05% +58.11% +57.67%
2021 2022 2023 2024 5-year trend
SG&A Expense
5.82M 5.01M 5.19M 5.30M
Research & Development
695.00K 492.00K 511.00K 657.00K
Other SG&A
5.13M 4.52M 4.68M 4.65M
SGA Growth
-16.95% -13.88% +3.51% +2.24%
Other Operating Expense
- - - -
-
Unusual Expense
- - (887.00K) 2.00K
-
EBIT after Unusual Expense
(784.00K) (183.00K) (663.00K) (68.00K)
Non Operating Income/Expense
13.00K (13.00K) 671.00K 4.00K
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
128.00K 135.00K 139.00K 145.00K
Interest Expense Growth
+13.27% +5.47% +2.96% +4.32%
Gross Interest Expense
128.00K 135.00K 139.00K 145.00K
Interest Capitalized
- - - -
-
Pretax Income
(899.00K) (331.00K) (131.00K) (209.00K)
Pretax Income Growth
+67.00% +63.18% +60.42% -59.54%
Pretax Margin
-12.53% -4.05% -1.68% -2.30%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(899.00K) (331.00K) (131.00K) (209.00K)
Minority Interest Expense
- - - -
-
Net Income
(899.00K) (331.00K) (131.00K) (209.00K)
Net Income Growth
+67.00% +63.18% +60.42% -59.54%
Net Margin Growth
-12.53% -4.05% -1.68% -2.30%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(899.00K) (331.00K) (131.00K) (209.00K)
Preferred Dividends
- - - -
-
Net Income Available to Common
(899.00K) (331.00K) (131.00K) (209.00K)
EPS (Basic)
-0.1148 -0.0414 -0.0164 -0.0261
EPS (Basic) Growth
+68.23% +63.94% +60.39% -59.15%
Basic Shares Outstanding
7.83M 8.00M 8.00M 8.00M
EPS (Diluted)
-0.1148 -0.0414 -0.0164 -0.0261
EPS (Diluted) Growth
+68.23% +63.94% +60.39% -59.15%
Diluted Shares Outstanding
7.83M 8.00M 8.00M 8.00M
EBITDA
(1.12M) 176.00K (469.00K) 140.00K
EBITDA Growth
+55.20% +115.71% -366.48% +129.85%
EBITDA Margin
-15.61% +2.15% -6.02% +1.54%

International Stem Cell Corp in the News